Healthcare

The global healthcare equipment leasing market is set to grow rapidly as hospitals, clinics, and diagnostic centers pursue asset-light models to combat capital strain. Between 2025 and 2030, market value is expected to expand from $54B to $98B (11.1% CAGR). Growth is driven by rising medical device costs, flexible financing needs, and government-backed leasing incentives across the U.S., Europe, and Asia-Pacific.

This report quantifies cell therapy commercialization across the US & EU (2025–2030), focusing on manufacturing scale-up and regulatory pathways. We model capacity, COGS, batch success, lot-release time, and vein-to-vein (V2V) alongside FDA/EMA review timelines, expedited routes, and CMC comparability risks. Results: closed/automated systems and digital QA reduce COGS 30–38%, lift batch success to ≥94%, and compress release to ~10–12 days. Regulatory acceleration (RMAT/BT/PRIME) lifts approvals 3.1× versus 2025, with ROI 20–27% for investors and sponsors achieving robust tech-ops readiness.

This report quantifies the clinical nutrition market across the US and UK (2025–2030), covering enteral, parenteral, and oral nutritional supplements (ONS). Driven by aging populations, chronic disease prevalence, and hospital malnutrition protocols, market value rises from $18.5B (2025) → $30.2B (2030) at a CAGR of 10.2%. Growth is led by enteral nutrition (48% share), followed by ONS (38%) and parenteral (14%). Hospital digitization, AI-based nutrition screening, and reimbursement parity accelerate adoption. ROI averages 16–22% for integrated hospital nutrition programs.

This report explores the healthcare facility management market across the US and EU (2025–2030), focusing on the growth trends, market size, and operational challenges. The market is expected to grow from $215B in 2025 to $350B by 2030 (CAGR 9.9%). Key drivers include increased demand for healthcare services, aging infrastructure, sustainability initiatives, and the integration of smart technologies in hospital operations. By 2030, smart hospital solutions will represent 30% of the market share, with energy-efficient systems and automated processes improving facility operations and cost savings. Healthcare providers are expected to focus on optimized facility management to reduce operational inefficiencies, maintenance costs, and improve patient experience.

Between 2025 and 2030, the skin cancer diagnostics and therapeutics market grows from $10.5B to $23.6B (CAGR 17.2%) across the USA, Europe, and MEA. Non-melanoma skin cancers remain the most common, driving demand for early diagnostic tools such as AI-powered imaging and genomic sequencing. Therapeutics expand as immune checkpoint inhibitors and targeted therapies for melanoma see rapid adoption, with the USA leading at 45% of the global market share. Meanwhile, Europe and MEA witness faster diagnostic adoption, particularly through mobile teledermatology and AI-based platforms.

This report quantifies the compression therapy market across the USA and EU (2025–2030), covering medical compression garments, multilayer bandage systems, intermittent pneumatic compression (IPC) pumps, and ancillary accessories. Market value rises from $4.6B (2025) to $7.5B (2030) at a CAGR ~10.3%, powered by aging demographics, chronic venous insufficiency (CVI), venous leg ulcers (VLU), lymphedema, and post-operative edema protocols. Growth accelerators include 3D body-scanning for custom fit, e-commerce/refill programs, and home-based IPC. Health systems report ulcer healing-time reductions 15–22%, recurrence −18–24%, and adherence +12–16 pp, yielding attractive, measurable ROI.

Between 2025 and 2030, space medicine commercialization in the USA expands significantly, growing from $1.8B to $7.4B (CAGR 32.1%). Microgravity research becomes increasingly crucial for developing space-specific therapeutics, and intellectual property (IP) strategies are refined for pharma and space-tech startups. Key advancements in drug development and biological research include tissue regeneration, bone-density treatments, and countermeasures for space-related diseases. IP portfolios expand, with 20+ patents being filed annually. The private sector is projected to secure 60% of the market by 2030, driven by NASA collaborations and private space ventures like SpaceX and Blue Origin.

Between 2025 and 2030, Europe’s obesity-meds reimbursement systems transition toward digitized prior authorization (PA) and AI-driven claims adjudication. The obesity-therapy market grows from €6.8B to €15.2B (CAGR 17.4%), while average PA turnaround time halves (22 → 11 days). First-pass approval rates improve 58% → 83%, and step-therapy duration shortens 3.8 → 2.1 months. Automated workflows reduce administrative cost per claim €118 → €84 (−29%), and appeals success climbs 42% → 71%. Digital harmonization under EMA guidance expands e-PA coverage to 79% of EU payers, yielding a payer ROI of ~21%.

From 2025 to 2030, global ICU infrastructure modernization accelerates, emphasizing infection containment and staff resilience. Negative-pressure isolation room adoption increases from 34% to 78% of tertiary hospitals across Asia, the US, and EU. Global ICU capex expands $29.6B → $61.3B (CAGR 15.8%), with hybrid modular builds reducing construction time −38%. AI-driven ventilation control systems lower airborne pathogen risk −46%, while ergonomic redesigns cut nurse fatigue scores −33%. Cumulatively, these improvements raise ICU operational uptime from 87% → 96%, enhancing care throughput and workforce retention.

This research explores AI-powered clinical trial matching systems in the UK and Europe (2025–2030), emphasizing natural language processing (NLP) accuracy, patient diversity in recruitment, and automation in eligibility parsing. It evaluates the market’s expansion as hospitals, CROs, and sponsors integrate AI for patient identification, consent optimization, and real-world data inclusion. The report quantifies accuracy gains, diversity representation metrics, and time-to-recruit reductions, guiding stakeholders toward ethical, scalable, and data-compliant AI deployment in clinical research.